NEW YORK, November 28, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members
with timely information, WallStEquities.com has issued free
tailored Stock Review on ONCE, AGEN, CHRS, and ACOR which is a
click away at http://www.wallstequities.com/registration. On
Monday, November 27, 2017, the NASDAQ
Composite ended the trading session at 6,878.52, down 0.15%; the
Dow Jones Industrial Average edged 0.10% higher, to finish at
23,580.78; and the S&P 500 closed at 2,601.42, slightly
dropping 0.04%. US markets saw seven out of nine sectors
finishing the day in red and two in green. This Tuesday,
WallStEquities.com has initiated reports coverage on the following
Biotechnology equities: Spark Therapeutics Inc. (NASDAQ: ONCE),
Agenus Inc. (NASDAQ: AGEN), Coherus Biosciences Inc. (NASDAQ:
CHRS), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Sign up today
for free and learn why our members refer to our research coverage
as the 'best out there':
http://www.wallstequities.com/registration
Spark Therapeutics
Philadelphia, Pennsylvania
headquartered Spark Therapeutics Inc.'s stock finished Monday's
session 3.13% lower at $71.79 with a
total trading volume of 373,758 shares. The Company's shares have
advanced 29.07% over the past twelve months and 43.87% since the
start of this year. The stock is trading above its 200-day moving
average by 6.45%. Additionally, shares of Spark Therapeutics, which
focuses on the development of gene therapy products for patients
suffering from debilitating genetic diseases, have a Relative
Strength Index (RSI) of 38.16.
On November 08th, 2017,
research firm RBC Capital Markets reiterated its 'Outperform'
rating on the Company's stock with a decrease of the target price
from $100 a share to $98 a share. Signing up now gives you access to
the free research coverage on ONCE at:
http://www.wallstequities.com/registration/?symbol=ONCE
Agenus
On Monday, shares in Lexington,
Massachusetts headquartered Agenus Inc. recorded a trading
volume of 662,335 shares. The stock ended the session 1.79% lower
at $3.85. The Company's shares have
advanced 8.15% in the last month. The stock is trading below its
50-day moving average by 5.92%. Moreover, shares of Agenus, which
focuses on the discovery and development of therapies that engage
the body's immune system for patients suffering with cancer, have
an RSI of 50.65. Get access to our top-rated research, including
the free report on AGEN at:
http://www.wallstequities.com/registration/?symbol=AGEN
Coherus Biosciences
Redwood City, California
headquartered Coherus Biosciences Inc.'s shares closed the day
1.71% lower at $8.60. The stock
recorded a trading volume of 822,200 shares, which was above its
three months average volume of 544.98 thousand shares. The stock is
trading below its 50-day moving average by 28.90%. Additionally,
shares of Coherus Biosciences, which focuses on developing and
commercializing biosimilar products worldwide, have an RSI of
32.42. Click here to subscribe for a free membership which welcomes
you with our report on CHRS at:
http://www.wallstequities.com/registration/?symbol=CHRS
Acorda Therapeutics
Shares in Ardsley, New York
headquartered Acorda Therapeutics Inc. finished 2.44% lower at
$20.00. The stock recorded a trading
volume of 657,808 shares. The Company's shares have advanced 6.38%
on an YTD basis. The stock is trading below its 50-day moving
average by 19.75%. Furthermore, shares of Acorda Therapeutics,
which identifies, develops, and commercializes therapies for
neurological disorders in the US, have an RSI of 37.36.
On November 16th, 2017,
research firm Stifel downgraded the Company's stock rating from
'Buy' to 'Hold' while revising its previous target price from
$26 a share to $15 a share. Join our big investor community at
Wall St. Equities today and start so with your free report on ACOR
at:
http://www.wallstequities.com/registration/?symbol=ACOR
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. WSE has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
WSE has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a
third-party research service company (the "Reviewer") represented
by a credentialed financial analyst [for further information on
analyst credentials, please email info@wallstequities.com.
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by WSE. WSE is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. WSE, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, WSE, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither WSE nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company, we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore
228
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Wall St. Equities